Medtronic Vascular, Neogyn, Palatin, Repros, Targacept,

Trimel, Vivus, Warner Chilcott. Allen D. Seftel is an advisor

for Auxilium Pharmaceuticals, Inc. Gregory J. Kaufman is

an employee of Auxilium Pharmaceuticals, Inc. Ted M.

Smith is an employee of Auxilium Pharmaceuticals, Inc.

James P. Tursi is an employee of Auxilium Pharmaceuticals,

Inc. Arthur L. Burnett is an investigator for Acorda

Therapeutics, American Medical Systems, Auxilium

Pharmaceuticals, Inc., Coloplast, Endo Pharmaceuticals,

National Institutes of Health, New England Research

Institute, P

zer, Inc., and a consultant for Auxilium

Pharmaceuticals, Inc., Genomic Health, Inc., Re

ﬂ

exonic LLC.

This study was funded by Auxilium Pharmaceuticals, and

funding to support the preparation of this manuscript was

provided by Auxilium Pharmaceuticals to MedVal.

References

Jalkut M

Gonzalez-Cadavid N

Rajfer J

. New discoveries in the basic

science understanding of Peyronie

’

s disease.

Curr Urol Rep

2004; 5:

478

–

Moreland RB

Nehra A

. Pathophysiology of Peyronie

’

s disease.

Int J

Impot Res

2002; 14: 406

–

Taylor FL

Levine LA

. Peyronie

’

s disease.

Urol Clin North Am

2007; 34:

517

–

Paulis G

Brancato T

.In

ﬂ

ammatory mechanisms and oxidative stress in

Peyronie

’

s disease: therapeutic

“

rationale

”

and related emerging treatment

strategies.

ﬂ

amm Allergy Drug Targets

2012; 11: 48

–

Nelson CJ

Diblasio C

Kendirci M

Hellstrom W

Guhring P

Mulhall

. The chronology of depression and distress in men with Peyronie

’

disease.

J Sex Med

2008; 5: 1985

–

Smith JF

Walsh TJ

Conti SL

Turek P

Lue T

. Risk factors for

emotional and relationship problems in Peyronie

’

s disease.

J Sex Med

2008; 5: 2179

–

Hellstrom WJG

Feldman R

Rosen RC

Smith T

Kaufman G

Tursi J

Bother and distress associated with Peyronie

’

s disease: validation of the

Peyronie

’

s Disease Questionnaire (PDQ).

J Urol

2013; 190: 627

–

Gelbard M

Hellstrom WJ

McMahon CG et al.

Baseline characteristics

from an ongoing phase 3 study of collagenase

Clostridium histolyticum

patients with Peyronie

’

s Disease.

J Sex Med

2013; 10: 2822

–

Ralph D

Gonzalez-Cadavid N

Mirone V et al.

The management of

Peyronie

’

s disease: evidence-based 2010 guidelines.

J Sex Med

2010; 7:

2359

–

10 Serefoglu EC

Hellstrom WJ

. Treatment of Peyronie

’

s disease: 2012

update.

Curr Urol Rep

2011; 12: 444

–

11 Chung E

Clendinning E

Lessard L

Brock G

. Five-year follow-up of

Peyronie

’

s graft surgery: outcomes and patient satisfaction.

J Sex Med

2010; 8: 594

–

600

12 Levine LA

Larsen SM

. Surgery for Peyronie

’

s disease.

Asian J Androl

2013; 15: 27

–

13 Green

eld JM

Lucas S

Levine LA

. Factors affecting the loss of length

associated with tunica albuginea plication for correction of penile

curvature.

J Urol

2006; 175: 238

–

14 Gur S

Limin M

Hellstrom WJ

. Current status and new developments in

Peyronie

’

s disease: medical, minimally invasive and surgical treatment

options.

Expert Opin Pharmacother

2011; 12: 931

–

15 Muller A

Mulhall JP

. Peyronie

’

s disease intervention trials:

methodological challenges and issues.

J Sex Med

2009; 6: 848

–

Xia

ﬂ

(collagenase Clostridium histolyticum) [prescribing information]

Chesterbrook, PA: Auxilium Pharmaceuticals, Inc., 2013

17 Gelbard M

Lipshultz LI

Tursi J

Smith T

Kaufman G

Levine LA

Phase 2b study of clinical ef

cacy and safety of collagenase

Clostridium

histolyticum

in patients with Peyronie

’

s disease.

J Urol

2012; 187: 2268

–

18 Gelbard MK

James K

Riach P

Dorey F

. Collagenase versus placebo in

the treatment of Peyronie

’

s disease: a double-blind study.

J Urol

1993;

149: 56

–

19 Jordan GH

. The use of intralesional clostridial collagenase injection

therapy for Peyronie

’

s disease: a prospective, single-center, non-placebo-

controlled study.

J Sex Med

2008; 5: 180

–

20 Gelbard M

Goldstein I

Hellstrom WJG et al.

Clinical ef

cacy, safety

and tolerability of collagenase

Clostridium histolyticum

for the treatment

of Peyronie disease in 2 large double-blind, randomized, placebo

controlled phase 3 studies.

J Urol

2013; 190: 199

–

207

21 Paulis G

Brancato T

’

Ascenzo R et al.

cacy of vitamin E in the

conservative treatment of Peyronie

’

s disease: legend or reality? A

controlled study of 70 cases.

Andrology

2013; 1: 120

–

Correspondence:

Larry I. Lipshultz, Scott Department of

Urology, Baylor College of Medicine, O

’

Quinn Medical Tower

at St. Luke

’

s, 6624 Fannin St., Ste 1700, Houston, TX 77030,

USA.

e-mail:

larryl@bcm.tmc.edu

Abbreviations:

CCH collagenase

Clostridium histolyticum

;PD

Peyronie

’

s disease; IMPRESS Investigation for Maximal

Peyronie

’

s Reduction Ef

cacy and Safety Study; IIEF

International Index of Erectile Function; AE adverse event;

PDQ Peyronie

’

s Disease Questionnaire; mITT modi

intention-to-treat.

656

Lipshultz

et al.